Our Integrated Antibacterial Discovery teams bring to our customers a long heritage, strong expertise and effective established networking with KOLs and relevant Institutions worldwide.
Our Antibacterial Discovery platform provides end-to-end solution from the very early phases (HTS screening by phenotypic screening) to the selection of the clinical candidates by applying translational-based modelling based on PK/PD readout, through bacterial target validation.
The proprietary Bacterial Culture Collections, comprised of more than 700 bacterial clinical isolates, allows tailored in vitro and in vivo assessment of new chemical entities (NCEs) profile and novel approaches against bacterial infections. Specifically-engineered isogenic strains are available for evaluating the role played by membrane permeability and can be used both for HTS purposes (phenotypic screen) and for understanding the mode by the macromolecule synthesis assay (MMS) available for ESKAPE pathogens.
Specific assays aimed to evaluate biofilm formation, expression of virulence factors, effect of specific treatment on bacterial population of persisters, bacterial fitness, inhibitory effect of new compounds on specific bacterial enzymes (e.g. Surface Plasmon Resonance with IMP, NDM, and VIM metallo-ß-lactamases) have been developed.
A full set of animal models of bacterial infections in rodents permits an in-depth evaluation of the efficacy of new antibacterial therapies and of translatability to human by coupling the PK and PD properties of compounds. Variety of read-outs can be flexibly combined and study design adapted: survival rates, CFU in tissues (planktonic vs. persister populations), drug’s exposure even in specific tissues of interest (e.g. BAL/ELF), biofilm biomass (early and late), biomarkers of inflammation/infection and virulence factor expression are some of the read-outs recorded in our study, made possible by the integration with Discovery DMPK, Immunology and Histopathology. Imaging techniques are consistently applied to different models thanks to the use of bioluminescent bacteria, thus allowing real-time evaluation of the development of the infection and higher compliance with the new Regulatory standards on animal use in research.
Tailored models such as endocarditis, human foreign body, UTI and chronic lung infection by P. aeruginosa complete the list of models available in Verona, which includes septicaemia, thigh, lung, skin infections and more.